"
Team:Imperial College London/Drylab/Protein Production
From 2009.igem.org
(Difference between revisions)
| Line 19: | Line 19: | ||
| - | This module is an integral part of the design, as large-scale commercialization of the drug of interest depends on finding the optimal conditions for protein production | + | This module is an integral part of the design, as large-scale commercialization of the drug of interest depends on finding the optimal conditions for protein production. |
<html><a href="https://2009.igem.org/Team:Imperial_College_London/Drylab/Protein_production/Analysis"><img style="vertical-align:bottom;" width=90px align="left" src="http://i691.photobucket.com/albums/vv271/dk806/II09_Learnmore.png"></a></html> about the model assumptions and predictions! | <html><a href="https://2009.igem.org/Team:Imperial_College_London/Drylab/Protein_production/Analysis"><img style="vertical-align:bottom;" width=90px align="left" src="http://i691.photobucket.com/albums/vv271/dk806/II09_Learnmore.png"></a></html> about the model assumptions and predictions! | ||
Revision as of 11:57, 6 October 2009
- Overview
- The model
- Simulations
Protein Production
Based on the Genetic circuit, a LacI-IPTG inducible promoter is responsible for kickstarting the production of the drug.
- In the absence of IPTG, LacI represses the production of the drug (Cellulase or PAH)
- When IPTG is introduced, the LacI repressing pathway is “de-repressed”, and some output protein is produced.
Our goals
The modelling aims to provide an overview and better understanding of the M1 system’s function by:
- Characterizing the system.
- Modeling to account for several factors that may reduce/hinder the production of the protein drug such as:
- Lac promoter leakiness
- IPTG toxicity
- Stability of output protein
This module is an integral part of the design, as large-scale commercialization of the drug of interest depends on finding the optimal conditions for protein production.
about the model assumptions and predictions!
